Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01141023
Registration number
NCT01141023
Ethics application status
Date submitted
8/06/2010
Date registered
10/06/2010
Date last updated
14/11/2023
Titles & IDs
Public title
Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression
Query!
Scientific title
The Parkinson's Progression Markers Initiative (PPMI)
Query!
Secondary ID [1]
0
0
PPMI-001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
PPMI
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Parkinson Disease
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Parkinson's disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - DaTscan
Experimental: Datscan SPECT Imaging - Subjects will b injected with 3-5 mCi of dopamine transporter. Within a 4 hour (+/- 30 minutes) window following the injection, subjects will undergo SPECT imaging on the camera.
Treatment: Drugs: DaTscan
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Mean Rates of Change
Query!
Assessment method [1]
0
0
The mean rates of change and the variability around the mean of clinical, imaging and biomic outcomes in early PD patients, and where appropriate the comparison of these rates between PD patient subsets and between various subsets (including, but not limited to: PD vs. healthy subjects, PD vs. SWEDD, PD vs. prodromal, PD with and without LRRK2, GBA or SNCA mutation, unaffected LRRK2, GBA or SNCA mutation carriers vs. healthy controls) at study intervals ranging from 3 months to 36 months. Specific examples of outcomes include MDS-UPDRS, dopamine transporter imaging striatal uptake, vesicular monoamine transporter type-2 uptake, and serum and CSF alpha-synuclein. PD patient subsets may be defined by baseline assessments, genetic mutations, progression milestones and/or rate of clinical, imaging, or biomic change.
Query!
Timepoint [1]
0
0
Baseline to 156 months
Query!
Secondary outcome [1]
0
0
Comparison between Rates of Change
Query!
Assessment method [1]
0
0
Comparison between the rates of change in the mean of clinical, imaging and biomic outcomes in various subsets (including, but not limited to: early PD vs. healthy subjects, PD vs. SWEDD, PD vs. prodromal, PD with and without LRRK2, GBA or SNCA mutation, unaffected LRRK2, GBA or SNCA mutation vs. healthy controls)
Query!
Timepoint [1]
0
0
Study intervals ranging from 3 months to 156 months
Query!
Secondary outcome [2]
0
0
Prevalence of measures of clinical, imaging and biomic outcomes in various subsets (
Query!
Assessment method [2]
0
0
Including, but not limited to: early PD patients, healthy subjects, PD vs SWEDDs, PD vs prodromal, PD with and without LRRK2, GBA or SNCA mutation, unaffected LRRK2, GBA or SNCA mutation carriers vs. healthy subjects.
Query!
Timepoint [2]
0
0
study intervals ranging from baseline to 156 months.
Query!
Secondary outcome [3]
0
0
Predictive Value
Query!
Assessment method [3]
0
0
To establish the predictive value of early clinical non-motor features, baseline imaging and biomic outcomes for future course of disease.
Query!
Timepoint [3]
0
0
Baseline to 156 months
Query!
Secondary outcome [4]
0
0
To examine the proportion of SWEDD subjects that have a change in their clinical management at 24 months
Query!
Assessment method [4]
0
0
SWEDD Clinical Diagnosis and Management Questionnaire.
Query!
Timepoint [4]
0
0
Baseline to 156 Months
Query!
Secondary outcome [5]
0
0
Exploratory Analysis
Query!
Assessment method [5]
0
0
Exploratory analysis to estimate the percentage of Prodromal subjects with one or more risk characteristics [hyposmia (<10th percentile for age and gender), RBD, or LRRK2, GBA or SNCA genetic mutation, and baseline DaTSCAN binding showing minimal to moderate DAT deficit] that phenoconvert to PD within 2 years, and an exploratory analysis to examine whether the baseline DaTSCAN binding or progression of clinical, imaging, or biospecimen markers may predict those subjects likely to phenoconvert.
Query!
Timepoint [5]
0
0
Baseline to 156 months
Query!
Eligibility
Key inclusion criteria
Parkinson Disease (PD) Subjects:
- A diagnosis of Parkinson disease for 2 years or less at Screening.
- Confirmation from imaging core that screening DAT scan is consistent with dopamine
transporter deficit, or if applicable a VMAT-2 PET scan consistent with vesicular
monoamine transporter deficit.
- Not expected to require PD medication with at least 6 months from Baseline.
- Male or female age 30 years or older at time of PD diagnosis.
Healthy Control (HC) Subjects:
• Male or female age 30 years or older at Screening.
Query!
Minimum age
30
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Parkinson Disease (PD) Subjects:
- Currently taking levodopa, dopamine agonists, MAO-B inhibitors, amantadine or other PD
medication.
- Has taken levodopa, dopamine agonists, MAO-B inhibitors or amantadine within 60 days
of Baseline.
- Has taken levodopa or dopamine agonists prior to Baseline for more than a total of 60
days.
- Received any of the following drugs that might interfere with DAT imaging:
Neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or
amphetamine derivative, within 6 months of Screening.
- Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude
safe completion of the lumbar puncture.
If applicable, currently taking medications that are known to cause QT-prolongation, or are
currently taking tetrabenazine (TBZ or amphetamine type medications.
- Condition that precludes the safe performance of routine lumbar puncture, such as
prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant
coagulopathy or thrombocytopenia.
- Use of investigational drugs within 60 days prior to Baseline (dietary supplements
taken outside of a clinical trial are not exclusionary, e.g., coenzyme Q10).
Healthy Control (HC) Subjects:
- Current or active neurological disorder.
- First degree relative with idiopathic PD (parent, sibling, child).
- MoCA score < 26.
- Received any of the following drugs that might interfere with DAT imaging:
Neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or
amphetamine derivative, within 6 months of Screening.
If applicable, currently taking medications that are known to cause QT-prolongation, or are
currently taking tetrabenazine (TBZ) or amphetamine type medications.
- Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude
safe completion of the lumbar puncture.
- Condition that precludes the safe performance of routine lumbar puncture, such as
prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant
coagulopathy or thrombocytopenia.
- Use of other investigational drugs within 60 days prior to baseline (dietary
supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme
Q10).
SWEDD Subjects:
All PD criteria apply, as above, except a SWEDD subject must have confirmation from imaging
core that screening dopamine transporter SPECT scan shows no evidence of dopamine
transporter deficit or if applicable a VMAT-2 PET scan shows no evidence of vesicular
monoamine transporter deficit.
Prodromal Subjects:
Inclusion Criteria (Prodromal Subjects) 4.2.7.1. Subjects must have at least one of the
following characteristics:
Hyposmia:
1. Male or female age 60 years or older
2. Confirmation from olfactory core that olfaction as determined by UPSIT is at or below
the 10th percentile by age and gender
REM Behavior Disorder (RBD):
1. Male or female age 60 years or older
2. Confirmation from sleep core that subject's Polysomnography (PSG) meets criteria for
RBD
LRRK2:
1. Male or female age 60 years or older
2. Written confirmation or documentation from testing facility that the individual is
LRRK2 mutation positive 4.2.7.2. Confirmation from imaging core that screening
dopamine transporter SPECT scan is read as eligible (see below). About 80 subjects
will have a range of DAT deficit similar to subjects with early PD (mild to moderate
DAT deficit). About 20 subjects will be selected with no DAT deficit or minimal DAT
deficit similar in age, gender, and risk profile to those with mild to moderate DAT
deficit. 4.2.7.3. Ability to provide written informed consent in accordance with Good
Clinical Practice (GCP), International Conference on Harmonization (ICH), and local
regulations. 4.2.7.4. Willing and able to comply with scheduled visits, required study
procedures and laboratory tests. 4.2.7.5. Women may not be pregnant, lactating or
planning pregnancy during the course of the study. Includes a negative urine pregnancy
test on day of screening scan prior to injection (DaTSCAN).
Exclusion Criteria (Prodromal Subjects)
1. Current or active clinically significant neurological disorder or psychiatric disorder
(in the opinion of the Investigator).
2. GDS score greater than or equal to 10 (GDS score of 5 - 9 requires Investigator
discretion to enter study).
3. STAI Form Y-1 greater than or equal to 54 requires Investigator discretion to enter
study.
4. A clinical diagnosis of dementia63 as determined by the investigator (Appendix 1).
5. A clinical diagnosis of Parkinson disease at the Screening visit as determined by the
Investigator.
6. Received any of the following drugs that might interfere with dopamine transporter
SPECT imaging: Neuroleptics, metoclopramide, alpha methyldopa, methylphenidate,
reserpine, or amphetamine derivative, within 6 months of Screening.
7. Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude
safe completion of the lumbar puncture.
8. Condition that precludes the safe performance of routine lumbar puncture, such as
prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant
coagulopathy or thrombocytopenia.
9. Any other medical or psychiatric condition or lab abnormality, which in the opinion of
the investigator might preclude participation.
10. Use of investigational drugs or devices within 60 days prior to Baseline (dietary
supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme
Q10).
11. Previously obtained MRI scan with evidence of clinically significant neurological
disorder (in the opinion of the Investigator).
Genetic Cohort: Parkinson Disease Subjects - Inclusion:
1. Patients must have at least two of the following: resting tremor, bradykinesia,
rigidity (must have either resting remor or bradykinesia) or either asymmetric resting
tremor or asymmetric bradykinesia.
2. A diagnosis of Parkinson Disease for 7 years or less at screening.
3. Hoehn and Yahr state <4 at baseline
4. Male or female age 18 years or older
5. Willingness to undergo genetic testing and to be informed of genetic testing results.
6. Confirmation of mutation in LRRK2, GBA or SNCA
7. For subjects taking any drugs that might interfere with dopamine transporter SPECT
imaging (Neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine or
amphetamine derivative must be willing and able from a medical standpoint to hold the
medication for at least 5 half-lives prior to screening DatSCAN(TM) imaging.
Exclusion:
1. Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude
safe completion of the lumbar puncture.
2. Condition that precludes the safe performance of routine lumbar puncture, such as
prohibitive lumbar spinal disease, bleeding diathesis or clinically significant
coagulopathy or thrombocytopenia.
Genetic cohort - Unaffected Individuals
Inclusion:
1. Male or female age 45 years or older at baseline with LRRK2 or GBA mutation and/or
first degree relative with a LRRK2 or GBA mutation or
2. Male or female age 30 years or older at baseline with a SNCA mutation and/or a first
degree relative with a SNCA mutation.
3. Unaffected subjects at high risk of LRRK2, GBA or SNCA mutation due to first degree
relative with a LRRK2, GBA or SNCA mutation may choose either to be informed of the
results or remain unaware of the results.
4. Unaffected subjects from an ethnic or geographic group knkown to have relatively high
risk of LRRK2, GBA or SNCA mutation such as people of Ashkenazi Jewish or Basques
descent) and who have a family member (either alive or deceased) who has/had PD must
be willing to be informed of their own testing results.
5. Willingness to undergo genetic testing
6. For subjects taking any of the following drugs that might interfere with dopamine
transporter SPECT imaging (neuroleptics, metoclopramide, alpha methyldopa,
methylphenidate, reserpine or amphetamine derivative) must be willing and able from a
medical standpoint to hold the medication for at least 5 half-lives prior to DatSCAN
imaging.
Exclusion:
1. A clinical diagnosis of PD
2. Current treatment with anticoagulants (e.g. coumadin, heparin) that might preclude
safe completion of the lumbar puncture.
3. Condition that precludes the safe performance of routine lumbar puncture, such as
prohibitive lumbar spinal disease, bleeding diathesis or clinically significant
coagulopathy or thrombocytopenia.
Genetic Registry - Inclusion:
1. Individual with a LRRK2, GBA or SNCA mutation and/or a first degree relative with a
LRRK2, GBA or SNCA mutation.
2. Male or female age 18 years or older
3. Willingness to undergo genetic testing, but may choose either to be informed of the
results or remain unaware of the results.
Query!
Study design
Purpose of the study
Other
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
30/06/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
952
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Macquarie University - Sydney
Query!
Recruitment postcode(s) [1]
0
0
NSW2109 - Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Oregon
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Pennsylvania
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Washington
Query!
Country [16]
0
0
Austria
Query!
State/province [16]
0
0
Innsbruck
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Paris
Query!
Country [18]
0
0
Germany
Query!
State/province [18]
0
0
Kassel
Query!
Country [19]
0
0
Germany
Query!
State/province [19]
0
0
Tuebingen
Query!
Country [20]
0
0
Greece
Query!
State/province [20]
0
0
Athens
Query!
Country [21]
0
0
Israel
Query!
State/province [21]
0
0
Tel Aviv
Query!
Country [22]
0
0
Italy
Query!
State/province [22]
0
0
Napoli
Query!
Country [23]
0
0
Italy
Query!
State/province [23]
0
0
Salerno
Query!
Country [24]
0
0
Norway
Query!
State/province [24]
0
0
Trondheim
Query!
Country [25]
0
0
Spain
Query!
State/province [25]
0
0
Barcelona
Query!
Country [26]
0
0
Spain
Query!
State/province [26]
0
0
San Sebastian
Query!
Country [27]
0
0
United Kingdom
Query!
State/province [27]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Ken Marek, MD
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
Institute for Neurodegenerative Disorders
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a observational, multi-center study to assess progression of clinical features,
imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy
controls (HC) and in PD patient subtypes.
The primary objective of this study is to identify clinical, imaging and biologic markers of
PD progression for use in clinical trials of disease-modifying therapies.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01141023
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Kenneth L Marek, MD
Query!
Address
0
0
Institute for Neurodegenerative Disorders
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01141023
Download to PDF